# Sodium Channel Blockers (Potassium Sparing Diuretics)

## Examples

- `amiloride`
- `triamterene`

## Mechanism of Action (MOA)

- Act on the **late distal convoluted tubule and collecting duct**.
- **Directly block epithelial Na⁺ channels (ENaC)** on the luminal membrane of principal cells.
- ↓ Na⁺ reabsorption → ↓ lumen-negative potential → ↓ K⁺ and H⁺ secretion.
- **Result:** Mild natriuresis with **K⁺ retention**.
- _Independent of aldosterone_ (unlike `spironolactone`).

![Potassium Sparing Acting](/pharmacology/cvs/anti-hypertensives/diuretics/potassium-sparing-acting.png)

## Pharmacodynamics (Effects)

- Weak diuretic effect (only ~2–3% of filtered Na⁺).
- **K⁺-sparing** — prevents hypokalemia caused by thiazides or loop diuretics.
- **Minimal effect on Ca²⁺ and Mg²⁺ excretion.**
- Little or no effect on systemic vascular resistance.

## Pharmacokinetics

| Property             | Notes                                                                        |
| :------------------- | :--------------------------------------------------------------------------- |
| **Absorption**       | Oral; well absorbed.                                                         |
| **Onset / Duration** | Slower onset than loop/thiazide; lasts 12–24 h.                              |
| **Metabolism**       | `amiloride` excreted unchanged in urine; `triamterene` metabolized in liver. |
| **Excretion**        | Mainly renal.                                                                |

## Indications

- **Used with thiazide or loop diuretics** to prevent K⁺ loss.
- **Hypertension** — as _add-on_ to reduce thiazide-induced hypokalemia.
- **Edematous states** — CHF, hepatic cirrhosis, nephrotic syndrome (with other diuretics).
- **Liddle’s syndrome[^1]** — (genetic overactivation of ENaC) — `amiloride` is drug of choice.

[^1]: **Liddle’s syndrome**: is a rare genetic disorder causing severe, early-onset high blood pressure (hypertension) due to a defect in kidney function, leading to the retention of too much sodium and water, and excretion of too much potassium.

## Adverse Effects

| Effect                                                                                                                            | Notes                                                       |
| :-------------------------------------------------------------------------------------------------------------------------------- | :---------------------------------------------------------- |
| **Hyperkalemia**                                                                                                                  | Most important; risk ↑ with renal impairment or ACEIs/ARBs. |
| **Metabolic acidosis**                                                                                                            | ↓ H⁺ excretion.                                             |
| **Nausea, vomiting**                                                                                                              | Mild GI upset.                                              |
| **Headache, dizziness**                                                                                                           | Occasional.                                                 |
| **Triamterene** — may cause **megaloblastic anemia** (interferes with folate metabolism) and **nephrolithiasis** (kidney stones). |                                                             |

## Cautions

- **Renal impairment** — risk of hyperkalemia.
- **Concurrent ACEIs, ARBs, or MRAs** — additive K⁺ retention.
- **Elderly** — reduced renal reserve increases risk of K⁺ toxicity.

## Contraindications

- **Hyperkalemia (>5.0 mmol/L)**.
- **Severe renal failure (anuria).**
- **Concomitant potassium supplements.**
